Published in J Infect Dis on August 01, 1979
The life and times of the Enterococcus. Clin Microbiol Rev (1990) 16.58
Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother (1989) 5.28
Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother (1990) 3.67
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother (1994) 3.02
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem? J Clin Microbiol (1989) 2.51
Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother (1991) 2.35
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
Genetic diversity among Enterococcus faecalis. PLoS One (2007) 2.32
Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother (1991) 2.31
Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol (1992) 2.23
Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother (1993) 2.19
High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J Clin Microbiol (1988) 2.11
Broad geographical distribution of homologous erythromycin, kanamycin, and streptomycin resistance determinants among group D streptococci of human and animal origin. Antimicrob Agents Chemother (1986) 2.07
Rapid identification of enterococci. J Clin Microbiol (1983) 2.03
Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J Clin Microbiol (1991) 1.98
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Comparative evaluation of the API 20S system and the automicrobic system gram-positive identification card for species identification of streptococci. J Clin Microbiol (1984) 1.82
Streptococcus faecium outbreak in a neonatal intensive care unit. J Clin Microbiol (1984) 1.81
Susceptibility testing of clinical isolates of Enterococcus faecium and Enterococcus faecalis. J Clin Microbiol (1992) 1.67
Laboratory detection of high-level aminoglycoside-aminocyclitol resistance in Enterococcus spp. J Clin Microbiol (1988) 1.63
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol (1988) 1.58
Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci. Antimicrob Agents Chemother (1990) 1.56
High-level aminoglycoside resistance in group A, B, G, D (Streptococcus bovis), and viridans streptococci. Antimicrob Agents Chemother (1982) 1.47
Overexpression and characterization of the chromosomal aminoglycoside 6'-N-acetyltransferase from Enterococcus faecium. Antimicrob Agents Chemother (1997) 1.44
Emergence of 4',4"-aminoglycoside nucleotidyltransferase in enterococci. Antimicrob Agents Chemother (1990) 1.39
Conjugative R plasmids in Streptococcus faecium (group D). Antimicrob Agents Chemother (1982) 1.35
Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections. Antimicrob Agents Chemother (1985) 1.28
Screening and treatment of infections caused by resistant enterococci. Antimicrob Agents Chemother (1991) 1.26
Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci. Antimicrob Agents Chemother (1989) 1.26
Antimicrobial resistance among enterococci. Antimicrob Agents Chemother (1991) 1.25
Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother (1992) 1.18
In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother (1989) 1.17
Correlation of penicillin-induced lysis of Enterococcus faecium with saturation of essential penicillin-binding proteins and release of lipoteichoic acid. Antimicrob Agents Chemother (1990) 1.17
Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother (1985) 1.16
Role of immunoblotting in the diagnosis of culture negative and enterococcal endocarditis. J Clin Pathol (1987) 1.09
Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiol Infect (1989) 1.05
Species identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patients. Antimicrob Agents Chemother (1991) 1.05
Rapid identification of group D streptococci with the API 20S system. J Clin Microbiol (1983) 0.98
Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis. Antimicrob Agents Chemother (2005) 0.97
Chromosomally mediated high-level gentamicin resistance in Streptococcus mitis. Antimicrob Agents Chemother (1993) 0.96
Evaluation of the Vitek GPS-TA card for laboratory detection of high-level gentamicin and streptomycin resistance in enterococci. J Clin Microbiol (1991) 0.87
Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections. Curr Infect Dis Rep (2000) 0.86
In vitro antibacterial effects of cephalosporins. Drugs (1987) 0.84
Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother (1984) 0.83
The use of platensimycin and platencin to fight antibiotic resistance. Infect Drug Resist (2013) 0.82
Intrinsic resistance to aminoglycosides in Enterococcus faecium is conferred by the 16S rRNA m5C1404-specific methyltransferase EfmM. RNA (2010) 0.80
Enterococcus faecium meningitis. Arch Dis Child Fetal Neonatal Ed (1994) 0.77
Non-beta-lactamase-producing penicillin-resistant Enterococcus faecium in a clinical setting. Can J Infect Dis (1990) 0.75
Spontaneous peritonitis caused by Enterococcus faecium. J Clin Microbiol (1990) 0.75
The ineffectiveness of tobramycin combination therapy in Streptococcus faecium endocarditis. Yale J Biol Med (1984) 0.75
Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA (1997) 8.24
Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA (1998) 8.02
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med (1992) 6.30
Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med (1989) 6.29
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA (1989) 5.66
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother (1974) 5.19
Sexual harassment in medical training. N Engl J Med (1993) 4.93
Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med (1998) 4.81
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J Clin Invest (1978) 4.38
Role of toxigenic and invasive bacteria in acute diarrhea of childhood. N Engl J Med (1975) 4.23
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis (1975) 3.52
Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis (1975) 3.33
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med (1980) 3.03
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis (2001) 2.87
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. J Infect Dis (1984) 2.77
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med (1991) 2.77
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis. J Infect Dis (1974) 2.64
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome. Am J Med (1989) 2.58
Sinusitis of the maxillary antrum. N Engl J Med (1975) 2.57
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med (1982) 2.52
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis (1987) 2.32
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet (1989) 2.18
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother (2000) 2.18
Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med (2001) 2.17
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J Infect Dis (1985) 2.10
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis (1991) 2.07
The HIV epidemic and training in internal medicine. Challenges and recommendations. N Engl J Med (1989) 2.06
Uncomplicated acute bronchitis. Ann Intern Med (2000) 2.06
Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J Infect Dis (1975) 2.05
A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med (1998) 2.04
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
DNA polymorphisms among Escherichia coli isolated from bacteriuric women. J Infect Dis (1989) 2.02
Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis (1984) 2.00
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Methods to improve detection of pneumococci in respiratory secretions. J Clin Microbiol (1975) 1.94
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest (1983) 1.93
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis (1988) 1.90
In vitro susceptibility studies with josamycin and erythromycin. Antimicrob Agents Chemother (1976) 1.89
Role of the vegetation in experimental Streptococcus viridans endocarditis. Infect Immun (1974) 1.89
Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med (2001) 1.89
Multiple use of disposable insulin syringe-needle units. JAMA (1980) 1.89
Routine use of anaerobic blood cultures: are they still indicated? Am J Med (2000) 1.88
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88